|Mr. Sean E. Brynjelsen||Pres, CEO & Director||705.93k||N/A||1972|
|Mr. W. Wilson Troutman CPA||CFO, Treasurer & Sec.||396.48k||N/A||1954|
|Mr. Paul Stickler||Sr. VP of Sales & Marketing||N/A||N/A||N/A|
|Ms. Bharathi Devarakonda||Sr. VP of Regulatory Affairs & Product Devel.||N/A||N/A||N/A|
|Ms. Ingrid Hoos||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Mr. Scott Grossenbach||VP of Sales & Marketing||N/A||N/A||N/A|
|Mr. David Krempa CFA||VP of Bus. Devel.||N/A||N/A||N/A|
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.